{"groups":[{"description":"Pomalidomide 4 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle. Dexamethasone 40 mg PO once daily on Days 1, 8, 15, 22 of each 28-day cycle for those who are ≤ 75 years of age Dexamethasone 20 mg PO once daily on Days 1, 8, 15, 22 of each 28-day cycle for those who are \\> 75 years of age","id":"FG000","title":"Pomalidomide Plus Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Disease Progression (DP)"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Insufficient effect of Pomalidomide"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Investigator's judgement- DP"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Study terminated by sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"STARTED"},{"achievements":[{"comment":"Completed = participants with progressive disease were considered as completed.","groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Treatment phase discontinuation occurred when a participant had confirmed progressive disease, development of unacceptable toxicity, voluntary withdrawal or met other criteria for treatment discontinuation.","recruitmentDetails":"All study participants who were on pomalidomide were transferred to the post-marketing study and continued the study treatment when pomalidomide became commercially available."}